Clinical Trial Update: AKT Inhibitor in Oestrogen Positive Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of an AKT inhibitor for estrogen receptor-positive breast cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Invasive Breast Cancer

Drugs mentioned

• AKT inhibitor (AKT inhibitor)

Snippet

Sponsor: University of Nottingham | Conditions: Invasive Breast Cancer | Phase 2 | Status: COMPLETED